Cyclo-cross fans, brace yourselves for a heartbreaking announcement that will leave you stunned. One of the sport's brightest stars is stepping away from the bike for good, and the reason is both personal and profoundly impactful.
In a deeply emotional Instagram post, Eli Iserbyt, a name synonymous with cyclo-cross excellence, revealed his decision to retire from the sport. But here's where it gets even more poignant: he's been medically advised to stop cycling altogether, even at a recreational level, due to a persistent and debilitating femoral artery condition known as iliac artery endofibrosis (IAE).
This isn't just a career-ender; it's a life-altering diagnosis that raises questions about the long-term health risks athletes face. Iserbyt, a multiple World Cup winner, two-time under-23 world champion, and former elite national and European cyclo-cross champion, has amassed an impressive 54 career victories. His absence from this winter's races, despite consistently strong performances in the 2024-25 season, now makes heartbreaking sense.
The outpouring of support from fans, industry insiders, and fellow athletes has been overwhelming. Tom Pidcock, Mathieu van der Poel, and Wout van Aert—all giants in the sport—offered heartfelt messages of solidarity. Pidcock's Instagram reply, 'Sorry to hear this Eli. Thanks for the great battles… wish you well!' captures the sentiment shared by many.
But here's where it gets controversial: Iserbyt's condition is far from rare. IAE, characterized by the narrowing, scarring, or kinking of the femoral artery, has affected numerous professional cyclists, including Pauline Ferrand-Prévot, Amanda Spratt, Joe Dombrowski, and Zdeněk Štybar. It’s even been labeled an 'occupational hazard' in the sport. The prolonged hip-flexion posture cyclists adopt is a contributing factor, and some estimates suggest up to 20% of professional cyclists may be affected. Yet, despite growing awareness, the condition remains a silent threat to both pros and amateurs alike.
And this is the part most people miss: while Iserbyt's case is extreme, requiring him to abandon cycling entirely, many riders manage IAE through less drastic measures. These include reducing training intensity, adjusting bike fit, incorporating soft tissue work, and, in some cases, undergoing surgery. The question lingers: could Iserbyt's career have been saved with earlier intervention or alternative management strategies?
As we reflect on Iserbyt's remarkable career and this bittersweet farewell, it’s impossible not to wonder: How many other athletes are silently battling similar health issues? And what more can the sport do to protect its stars? Share your thoughts in the comments—let’s keep this important conversation going.
